Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase
Language English Country Netherlands Media print
Document type Journal Article
PubMed
2168691
DOI
10.1016/0166-3542(90)90070-n
PII: 0166-3542(90)90070-N
Knihovny.cz E-resources
- MeSH
- Adenine administration & dosage analogs & derivatives pharmacology MeSH
- Antiviral Agents pharmacology MeSH
- Phosphorylation MeSH
- Cells, Cultured MeSH
- Organophosphonates * MeSH
- Organophosphorus Compounds administration & dosage pharmacology MeSH
- Ribonucleotide Reductases antagonists & inhibitors MeSH
- Simplexvirus drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- 9-(S)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine MeSH Browser
- adefovir MeSH Browser
- Adenine MeSH
- Antiviral Agents MeSH
- Organophosphonates * MeSH
- Organophosphorus Compounds MeSH
- Ribonucleotide Reductases MeSH
Diphosphates of N-(S)-(3-hydroxy-2-phosphonylmethoxypropyl) and N-(2-phosphonylmethoxyethyl) derivatives of purine and pyrimidine heterocyclic bases inhibit HSV-1 encoded ribonucleotide reductase. Of the compounds studied, the most efficient inhibitors of CDP reduction (at 5.1 mumols.l-1) by the HSV-1-encoded enzyme are HPMPApp (IC50 = 0.9 mumols.l-1) and PMEApp (IC50 = 8 mumol.l-1). PMEApp does not inhibit the enzyme isolated from the mutant HSV-1 KOS strain PMEAr which is resistant to PMEA at a concentration of 100 micrograms/ml. The enzyme isolated from the PMEA-resistant virus strain is also insensitive to inhibitory effects of hydroxyurea and HPMPApp. Thus, the inhibitory potency of HPMPApp and PMEApp toward HSV-1 encoded ribonucleotide reductase might be connected with the anti-HSV activity of HPMPA and PMEA.
References provided by Crossref.org